Marker for predicting cisplatin drug sensitivity of triple negative breast cancer and application of marker

The invention discloses a marker for predicting cisplatin drug sensitivity of triple negative breast cancer and application of the marker. According to the invention, two markers TH and MAP2 genes/proteins related to the cisplatin sensitivity of the triple negative breast cancer are found by screening potential related genes. In subsequent experiments, through immunohistochemical staining of human triple negative breast cancer pathological sections, scoring of immunostaining results and statistical analysis of clinical characteristic information, it is found that expression quantities of TH and MAP2 proteins in triple negative breast cancer patients are related to reduced sensitivity to platinum drug chemotherapy and worse survival prognosis. Therefore, the two markers can be used as novel markers and therapeutic targets for predicting the cisplatin resistance and prognosis of the triple negative breast cancer. 本发明公开了一种预测三阴性乳腺癌顺铂药物敏感性的标志物及其应用。本发明通过对潜在关联基因的筛选，发现了两种与三阴性乳腺癌顺铂敏感性相关的标志物TH、MAP2基因/蛋白。后续实验通过对人三阴性乳腺癌病